On Thursday, March 3, Descartes will report its 2016 fourth quarter and annual results.
Abernethy says he is expecting Descartes will post EBITDA of $16-million on revenue of $48.3-million in the fourth quarter, numbers that are in-line with the street consensus.
The Industrial Alliance analyst says he will be watching for how Descartes mid-quarter acquisition of Oz Development strengthens its existing relationships with Netsuite and UPS. He says he is also keen to learn of progress on the partnership front, particularly with long-time partner SAP. And he says he will be scrutinizing forex headwinds, which he says have been a challenge for the Waterloo-based company, but one he expects to abate as 2016 moves on.
Descartes closed at a 52-week high of more than (U.S.) $20.00 to close 2015 to current prices under $17.00. Abernethy says the current price of Descartes represents a good entry point for investors.
“We would continue to be buyers of the stock ahead of the quarterly results, given the recent pullback in the stock from ~$20.00, the stability of its business model, and the history of resilient operational performance in the face of weak macro environments,” he says.
In a research update to clients yesterday, Abernethy maintained his “Buy” rating and one-year price target of (U.S.) $21.00 on Descartes Systems Group, implying a return of 28.4 per cent at the time of publication.
Roth Capital Markets analyst Suji Desilva raised his price target for Ambarella (Ambarella Stock Quote, Chart, News, Analysts, Financials NASDAQ:AMBA)… [Read More]
Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, told BNN Bloomberg’s Market Call on Aug.… [Read More]
Beacon Securities analyst Doug Cooper maintained a “Buy” rating and $5.00 target for NTG Clarity Networks (NTG Clarity Networks Stock… [Read More]
Research Capital analyst Andre Uddin lowered his target price for NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials… [Read More]
Research Capital analyst Andre Uddin maintained a “Speculative buy” rating and C$0.70 target price on Theralase Technologies (Theralase Technologies Stock… [Read More]
Paradigm Capital analyst Daniel Rosenberg reiterated a “Buy” rating and C$1.50 target price on Sabio Holdings (Sabio Holdings Stock Quote,… [Read More]